Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  November 16, 2016

Due to manufacturing deficiencies found during a routine inspection by the FDA, approval of sarilumab for treating RA has slowed until facility issues are resolved…

Filed under:Biologics/DMARDsDrug Updates Tagged with:apremilastpiclidenosonPsoriasisRheumatoid Arthritis (RA)sarilumab

Second Biosimilar Equivalent to Adalimumab

Michele B. Kaufman, PharmD, BCGP  |  November 9, 2016

A recent study established the equivalency of BI 695501, a biosimilar, to its reference product, adalimumab, for treating patients with rheumatoid arthritis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBI 695501BiosimilarsFDAFood and Drug AdministrationLabeling Changessafety warningtestosterone

Music May Help Reduce Pain

Kathryn Doyle  |  November 5, 2016

(Reuters Health)—As a complement to traditional pain relief tools, such as medication, listening to music may lessen acute or chronic pain related to cancer and other conditions, according to a new review. “We have seen and observed this effect in multiple clinical settings, such as medical hospitals and hospice-care facilities,” says author Dr. Jin Hyung…

Filed under:AnalgesicsDrug Updates Tagged with:musicmusic therapyOpioidsPainPain ManagementPain Medication

Treating the Athlete: New Thoughts on How to Prevent & Treat Arthritis in Athletes & Raise Their Awareness

Karen Appold  |  November 4, 2016

All athletes—amateur and professional—should understand their risks for developing injury-related arthritis. Rheumatologists and other physicians at the Hospital for Special Surgery in New York take a rapid approach to treating athletes, often considering intense physical therapy, innovative treatments and surgery much sooner than for the average patient—all to keep joints healthy and enable athletes to play for as long as possible…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:Exercise/physical therapyinjuryphysical fitnessPhysical Therapysecukinumab

Many Patients Discontinue Tofacitinib by Year 1; Fasinumab Promising for Pain

Michele B. Kaufman, PharmD, BCGP  |  November 2, 2016

A recent analysis found that about 10% of RA patients taking tofacitinib do not follow recommended guidelines and more than half stop treatment by one year…

Filed under:Biologics/DMARDsDrug Updates Tagged with:fasinumabFDAFood and Drug AdministrationNerve growth factor (NGF)osteoarthritis (OA)PainTofacitinibtreatment guidelines

ACR Opposes DXA Reimbursement Cuts

Kelly Tyrrell  |  October 31, 2016

The Centers for Medicare and Medicaid Services (CMS) plans to significantly reduce reimbursement for dual-energy X-ray absorptiometry (DXA),—used to measure bone density, diagnose osteoporosis and help prevent fractures—performed as a hospital outpatient service in the 2017 Hospital Outpatient Prospective Payment System (HOPPS). If finalized, by 2023 it will cut payment for the DXA testing by 37%….

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:bipartisan bill H.R.2461dual-energy x-ray absorptiometryDXAreimbursement cuts

Tocilizumab Designated as Breakthrough Therapy for GCA

Michele B. Kaufman, PharmD, BCGP  |  October 26, 2016

To speed the development of tocilizumab to treat giant cell arteritis (GCA), the FDA designated it as a breakthrough therapy earlier this month…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:FDAFood and Drug AdministrationGiant Cell Arteritisgiant cell arteritis (GCA)Gouthyperuricemialesinuradtocilizumab

15 Years of Clinician Educators & Scholars in Rheumatology

Arthritis Care & Research  |  October 25, 2016

Since 1999, 60 rheumatologists have received the Clinician Scholar Educator Award from the Rheumatology Research Foundation. These clinician educators have benefitted professionally from the award and have also dedicated themselves to the advancement of education. Most spend at least 30% of their time engaged in education, and awardees provide curriculum widely used in rheumatology fellowship programs…

Filed under:Education & TrainingResearch Rheum Tagged with:Arthritis Care & ResearchAwardsClinician Scholar Educator (CSE) AwardEducationRheumatology Research Foundation

Denosumab Linked to Rebound-Associated Fractures in Nine Patients

Reuters Staff  |  October 21, 2016

NEW YORK (Reuters Health)—Patients can develop rebound-associated vertebral fractures after stopping denosumab, a new report of nine cases shows. All of the patients were considered to be at low risk of fracture, and the fractures occurred within nine to 16 months of their last injection, Dr. Olivier Lamy and colleagues from Lausanne University Hospital in Switzerland…

Filed under:ConditionsOsteoarthritis and Bone DisordersProfessional Topics Tagged with:bone mineral density (BMD)bone turnover rebound (BTR)denosumabFracturesOsteoporosisosteoporosis treatmentsvertebral fracture

Proton Pump Inhibitor Use May Be Linked to Bone Mineral Density

Michele B. Kaufman, PharmD, BCGP  |  October 19, 2016

The use of proton pump inhibitors may lead to changes in bone mineral density and an increased risk of developing osteoporosis…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)denosumabGlucocorticoid-Induced OsteoporosisGlucocorticoidsOsteoporosisproton pump inhibitor (PPI)

  • « Previous Page
  • 1
  • …
  • 200
  • 201
  • 202
  • 203
  • 204
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences